KISQALI vs SIROLIMUS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. KISQALI and SIROLIMUS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KISQALI	SIROLIMUS
Rating	70/100	66/100
Pharmacy pays	—	~$48.61 /30
Type	RX	RX
Active ingredient	RIBOCICLIB SUCCINATE	SIROLIMUS
Manufacturer	Novartis	Apotex
Dosage forms	Tablet	Solution
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Breast Neoplasms	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

kisqali sirolimus

Rating

70/100

66/100

Pharmacy pays

—

~$48.61 /30

Type

Active ingredient

RIBOCICLIB SUCCINATE

SIROLIMUS

Manufacturer

Novartis

Apotex

Dosage forms

Tablet

Solution

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Breast Neoplasms

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Frequently asked questions

Which is better-rated, Kisqali or Sirolimus?

By our independent rating, Kisqali scores higher — 3.5 vs 3.3 out of 5 for Sirolimus. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Kisqali and Sirolimus?

Kisqali contains Ribociclib Succinate, while Sirolimus contains Sirolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.